US protection ending in 2027: Ear, nose and throat
As of the edition of 20 October 2026, 9 drugs have US protection that ends in 2027 in ear, nose and throat; 6 of them have at least one company on route B because of it.
Sources: FDA Orange Book and Purple Book, other approval registers.
9 drugs
| Drug | US protection | Status | Holder | Target | Route B rows |
|---|---|---|---|---|---|
| Anakinra | Ends 2027 (orphan exclusivity) | Marketed | Swedish Orphan Biovitrum | IL1R1 | 0 |
| Bevacizumab | Ends 2027 (orphan exclusivity) | Marketed | Roche | VEGFA | 2 |
| Fluticasone furoate | Ends 2027 (patent) | Marketed | GSK | NR3C1 | 0 |
| Ipilimumab | Ends 2027 (orphan exclusivity) | Marketed | Bristol Myers Squibb | CTLA4 | 1 |
| Mepolizumab | Ends 2027 (computed from the first US licence) | Marketed | GSK | IL5 | 0 |
| Nintedanib | Ends 2027 (exclusivity) | Marketed | Boehringer Ingelheim | FGFR1, FGFR2, FGFR3 | 9 |
| Pantoprazole | Ends 2027 (exclusivity) | Marketed | Pfizer | ATP4A | 1 |
| Sorafenib | Ends 2027 (patent) | Marketed | Bayer | BRAF, FLT1, FLT3 | 1 |
| Vorinostat | Ends 2027 (patent) | Marketed | Merck & Co. | HDAC1, HDAC2, HDAC3 | 4 |
Listed by name. A route B row is one company at one target; for a drug with one target that is the number of companies. US protection is the US only, and it is not the date generics or biosimilars can enter.
Which companies are on route B in 2027 in ear, nose and throat
In the product6 of these 9 drugs have at least one company on route B. Which companies, and their scores, are in the product.
Get this list with the companies, scores and sources as a fileRequest access. Nothing is shown until you do.